



## Complete if Known Substitute for form 1449A/PTO Confirmation No. 9643 Application Number 09/899,815 INFORMATION DISCLOSURE Filing Date July 9, 2001 STATEMENT BY APPLICANT First Named Inventor Lars LANNFELT (use as many sheets as necessary) **Group Art Unit** 1645 **Examiner Name** LANNFELT=1A 1 **Attorney Docket Number** Sheet


			J.S. PATENT DOCUMENTS	· ·	
Examiner Initials*	Cite No.1	0.1	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if (if	of onea position.		
00	AA	58542 4	FINDEIS, et al.	12-29-1998	
		MARIL			
<del> </del>	<u> </u>	TA TRADENESS			
		RAUGU			
<del></del> .	ļ				

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite	U.S. Patent Document			Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,	
	No.1	Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T⁵
00	AB	wo	9511994	A1	ATHENA NEUROSCIENCES, INC.	05-04-1995		
· 100	AC	wo	9 5 3 1 9 9 6	A1 ·	MILKHAUS LABORATORY	11-30-1995		
0€	AD	wo	9 9 2 7 9 4 4	A1	ATHENA NEUROSCIENCES, INC.	06-10-1999		
0e/	AE	wo	0039310	A1	THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC.	07-06-2000		
00	AF	wo	0072876	A2	NEURALAB LIMITED	12-07-2000		
				,				
·								

Examiner Signature	leagon	Date Considered	10/3/02	
-----------------------	--------	--------------------	---------	--

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



	Ž	OTHER PRIOR ART- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
00	AG	SCHENK, et al., Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP, Letters to Nature, 400:173-177 (July 8, 1999)	
00/	АН	ST. GEORGE-HYSLOP, et al., Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder, Letters to Nature, 347:194-197 (Sept. 13, 1990)	
00	Al	WIRAK, et al., Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice, Science, 253:323-325 (July 19, 1991)	
QC/	AJ	ST. GEORGE-HYSLOP, et al., The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21, Science, 235:885-890 (Feb. 20, 1987)	
pc/	AK	WALSH, et al., Amyloid β-Protein Fibrillogenesis, The Journal of Biological Chemistry, 272(35):22364-22372 (Aug 29, 1997)	
00/	AL	WEIDEMANN, et al., "Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein, Cell 57:115-126 (April 7, 1989)	
00	AM	GIULIAN, et al., The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease, The Journal of Biological Chemistry, 273(45):29719-29726 (Nov. 6, 1998)	
Notherst	AN	SHERRINGTON, et al., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease, Nature, 375:754-760 (June 29, 1995)	
100	AO	PALMERT, et al., The β-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid, Proc. Natl. Acad. Sci. USA, 86:6338-6342 (Aug. 1989)	
00/	AP	LEVY, et al., Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type, Science, 248:1124-1126 (June 1, 1990)	
Not	AQ	SUZUKI, et al., An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βΑΡΡ <sub>117</sub> ) Mutants, Science, 264:1336-1340 (May 27, 1994)	
100	AR	CONWAY, et al., Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy, PNAS, 97(2):571-576 (Jan. 18, 2000)	

Theung Am Examiner Date Signature Considered \* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered to the line of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.





Substitute for form 1449A/PTO	Complete If Known		
INFORMATION DISCLOSURE	Application Number 09/899,815	Confirmation No. 9645	
STATEMENT BY APPLICANT	Filing Date	July 9, 2001	
(use as many sheets as necessary)	First Named Inventor	Lar LANNFELT	
OIPE	Group Art Unit	1645	
0 8.7	Examiner Name		
Sheet 3 MAR 1 2 2007 3 of 4	Attorney Docket Number	LANNFELT=1A	

	OTHER PRIOR ART- NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>				
00	AS	MULLAN, et al., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid, Nature Genetics, 1:345-347 (Aug. 1992)					
00	AT	HENDRIKS, et al., Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene, Nature Genetics, 1:218-221 (June 1992)					
00	AU	DE JONGHE, et al., Flemish and Dutch Mutations in Amyloid β Precursor Protein Have Different Effects on Amyloid β Secretion, Neurobiology of Disease, 5:281-286 (accepted for publ., Aug. 19, 1998)					
00/	AV	KAMINO, et al., Linkage and Mutational Analysis of Familial Alzheimer Disease Kindreds for the APP Gene Region, Am. J. Hum. Genet. 51:998-1014 (revision received July 24, 1992)					
00/	AW	CITRON, et ai., Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice, Nature Medicine, 3(1):67-72 (January 1997)					
œ	AX	FORSELL, et al., Amyloid precursor protein mutation at codon 713 (Ala - Val) does not cause schizophrenia: non-pathogenic variant found at codon 705 (silent), Neuroscience Letters, 184:90-93 (accepted Nov. 18,. 1994)					
00	AY	HARDY, Amyloid, the presentlins and Alzheimer's disease, Trends Neurosci., 20(4):154-159 (1997)					
00/	AZ	GRABOWSKI, et al., Novel Amyloid Precursor Protein Mutation in an Iowa Family with Dementia and Severe Cerebral Amyloid Angiopathy, Ann. Neurol., 49:697-705 (published online March 19, 2001)					
00	ВА	SCHEUNER, et al., Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased <i>In vivo</i> by the presenilin 1 and 2 and <i>APP</i> mutations linked to familial Alzheimer's disease, Nature Medicine, 2(8):864-870 (Aug. 1996)					
ov	BB	SERPELL, Alzheimer's amyloid fibrils: structure and assembly, Biochimica et Biophysica Acta, 1502:16-30 (accepted Nov. 24, 1999)					
00	ВС	HARPER, et al., Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease, Biochemistry, 38:8972-8980 (published online June 18, 1999)					
6C/	BD	BACSKAI, et al., Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy, Nature Medicine, 7(3):369-372 (March 2001)					

Examiner Signature	Munfour	Date Considered	10/30/02	75
	<u> </u>			

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance accord considered. Include copy of this form with next communication to applicant.

\* Unique citation designation number. \* Applicant is to place a check mark here if English language Translation is attached.



amorphograph abunda pagas in the affection of the section to the first of



Substitute for form 1449A/PTO	Complete If Known		
INFORMATION DISCLOSURE	Application Number 09/899,815	Confirmation No. 9645	
STATEMENT BY APPLICANT	Filing Date	July 9, 2001	
fuse as many sheets as necessary)	First Named Inventor	Lar LANNFELT	
OIPE	Group Art Unit	1645	
	Examiner Name		
Sheet 4 MAR 1 2 2002 of 4	Attorney Docket Number	LANNFELT=1A	

3	OTHER PRIOR ART- NON PATENT LITERATURE DOCUMENTS	
Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
BE	FRENKEL,et al., Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration, PNAS, 97(21):11455-11459 (Oct. 10, 2000)	
BF	BARD, et al., Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, 6(8):916-919 (Aug. 2000)	
BG	MORGAN, et al., Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408:982-985 (Dec. 2000)	V
вн	JANUS, et al., Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408:979-982 (Dec. 2000)	
ВІ	CHEN, et al., A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease, Nature, 408:975-978 (Dec. 2000)	
	THECH C	,
	ENTER O	
	# 200, 11600/2	
		-
	BE  BF  BG  BH	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published  BE FRENKEL, et al., Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration, PNAS, 97(21):11455-11459 (Oct. 10, 2000)  BF BARD, et al., Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, 6(8):916-919 (Aug. 2000)  BG MORGAN, et al., Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408:982-985 (Dec. 2000)  BH JANUS, et al., Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408:979-982 (Dec. 2000)  BI CHEN, et al., A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease, Nature, 408:975-978

Examiner Signature Date Considered /0/30/02		61.8			
Signature Considered Considered	Examiner	Menelder	Date	10/30/02	
	Signature	cherry our	Considered	192902	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.